Gaucher disease is caused by mutations in the GBA gene, which encodes for the lysosomal enzyme β-glucocerebrosidase (GCase), resulting in the accumulation of storage material in visceral organs and in some cases the brain of affected patients. While there is a commercially available treatment for the systemic manifestations, neuropathology still remains untreatable. We previously demonstrated that gene therapy represents a feasible therapeutic tool for the treatment of the neuronopathic forms of Gaucher disease (nGD). In order to further enhance the therapeutic affects to the central nervous system, we systemically delivered an adeno-associated virus (AAV) serotype 9 carrying the human GBA gene under control of a neuron-specific promoter to a nGD mouse model. Gene therapy increased the life span of treated animals, rescued the lethal neurodegeneration, normalised the locomotor behavioural defects and ameliorated the visceral pathology. Together these results provided further indication of gene therapy as a possible effective treatment option for the neuropathic forms of Gaucher disease. Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddz317/5698692 by guest on 16 January 2020
Introduction
Gaucher disease (GD) is a metabolic condition and the most common lysosomal storage disorder (LSD) (1) . It is caused by mutations in the GBA gene that encodes for the lysosomal enzyme β-glucocerebrosidase (GCase) (2) .
Dysfunctional or absent GCase leads to the accumulation of the substrate glucosylceramide (GluCer) and other sphingolipids in cells of the body, contributing to multisystemic manifestations.
GD has been historically classified into three distinct types based on the absence (type 1), or presence and severity of central nervous system impairment (type 2 and type 3). The visceral manifestations are common to all three types of GD (3) with a hallmark of significant hepatosplenomegaly (4) and consequent pancytopenia (5) and, frequently, lung (6) and bone disease (7) . Histopathology of organs reveals the presence of the characteristic 'Gaucher cells' in the form of activated and engorged macrophages. A more contemporary and realistic clinical assessment considers that GD exhibits a continuum of phenotypes (1, 8) . For example, type 1 patients may occasionally present central or peripheral neurological manifestations (9, 10, 11) . Type 2, or acute neuronopathic GD (nGD), is the most severe form with perinatal onset and subsequent death by two to four years of age (12) . Type 3 is the chronic form of nGD, has a slower progression than type 2 and patients can live into adulthood (1, 13) .
Neuronopathic forms of GD are characterised by perivascular and parenchymal accumulation of Gaucher cells, accompanied by severe neuronal loss in the layer IV and V of the somatosensory cortex, the cornu ammonis hippocampal regions, the thalamic nuclei of the midbrain, cerebellum, pons and medulla in the brain stem (14) . Extensive astrogliosis and microglia activation further contribute to neuroinflammation and neuronal death (15) , which are also reported in the nGD mouse model (16, 17) . The earliest neurological symptoms manifest in the first months of life with horizontal gaze palsy, hypertonic posturing, head retroflexion and swallowing difficulties (18) . The severe neurodegeneration progresses rapidly, and early death usually occurs following extensive brain stem damage leading to laryngospasm and aspiration pneumonia (19) .
Although enzyme replacement therapy is effective in reducing the systemic manifestations in the viscera, it is not efficacious in addressing the neurological symptoms of nGD since the recombinant enzyme cannot cross the blood-brain barrier. Therefore, there is currently no effective treatment for the type 2 or 3 neuropathology and there is an overwhelming need to develop novel therapies.
Gene therapy is an attractive option for the treatment of nGD. We previously demonstrated that brain-targeted fetal and neonatal gene therapy using AAV9 vector rescued an acute mouse model of type 2 nGD (20) . However, since the gene therapy was directed to the brain, the visceral organs continued to develop severe pathology. Using the ability of AAV9 to cross the blood-brain barrier (21, 22, 23, 24) we administered gene therapy intravenously. All treated mice were rescued from premature death associated to neurodegeneration, and long-term improvements in visceral pathology were reported. While the results were highly encouraging given the severity of the nGD mouse model, the brain of treated mice was not completely free of pathology following neonatal intervention.
In the present study, we designed a novel vector which improves transgene expression in the central nervous system of a Gba knock-out K-14-lnl/lnl mouse model (25) following systemic administration to neonatal mice. Neuron-specific gene delivery under control of the strong human Synapsin I (hSynI) promoter has proven successful in a intracerebroventricular gene therapy pre-clinical study on another LSD characterised by severe neuropathology (26) . Here we used a similar vector configuration and intravenously administered gene therapy to neonatal mice. We conducted an initial biodistribution study and analyse the safety of the new viral vector following intravenous administration. Finally, we assessed extension in life span, behavioural improvements and pathological markers in the brain and visceral organs of treated Gba knock-out animals.
Results eGFP expression profile following intravenous administration of

AAV9.hSYNI.eGFP to neonatal mice.
We first conducted experiments to assess the expression profile of an AAV9 vector that drives expression of the eGFP reporter gene under control of the neuron specific hSynI promoter. This vector also included the human growth hormone polyA and woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) sequences ( Figure 1A ). Three wild-type mice were injected into the temporal vein at day of birth with 2x10 11 viral vector genomes (vg) of AAV9.hSYNI.eGFP. Three uninjected littermates were used as negative agematched controls. The animals were sacrificed at post-natal day 30 (P30), and eGFP expression analysis was carried out on the harvested tissues.
Brain sections of injected and uninjected mice were stained with antibody against eGFP and light microscopy analysis was performed. The systemic administration of the viral vector resulted in widespread transduction throughout the whole brain ( Fig. 1B ). Intense eGFP expression was detected in areas of particular relevance to nGD including layer V of the cortex, the dentate gyrus and CA1/CA2 region in the hippocampus, the thalamus, cerebellar lobules and in the gigantocellular nuclei region in the brain stem. Higher magnification light microscopy images in Fig. 1B revealed that transduced cells appeared to have a neuronal morphology. To confirm that eGFP gene expression was specific to neurons and not other glial cells, brain sections were co-stained with fluorescent antibodies for eGFP and the neuronal marker NeuN and counterstained with the nucleic acid marker DAPI ( Fig 1C) . In the brains of injected mice it was possible to identify NeuN-positive cells expressing the eGFP protein (white arrows). Brain sections were also stained with antibody for the glial fibrillary acidic protein GFAP ( Fig 1D) . eGFP expression (white arrow) was not present in any cells identified as GFAP-positive, confirming the neuronspecific expression profile of the AAV9.hSYNI.eGFP vector.
Interestingly, an examination of various visceral organs from administered mice revealed extensive eGFP expression compared to control unadministered mice.
This was most prominent in the liver, but also visible in the spleen, lung and heart ( Fig. 1E ). Therefore, the hSynI promoter in the context of this AAV backbone mediates not only neuron specific expression in the brain but also expression in various visceral organs, which is sustained through rapid growth from the neonatal to adult phase of murine development.
In vitro functionality assessment of AAV9.hSYNI.hGBA and evaluation of neuroinflammatory response in wild-type mice.
Having confirmed robust hSynI-mediated eGFP expression in neurons of the murine brain and also cells of visceral organs, we replaced the transgene with the human GBA cDNA sequence (pAAV9.hSynI.GBA) ( Figure 2A ). To confirm whether correct full length GCase protein was expressed, HEK-293T cells were transfected with the plasmid described in Fig. 2A . Untransfected cells were used as a control. A Western blot analysis using antibodies against GCase and β-actin as loading control was performed on cell lysates. Cells transfected with the pAAV9.hSynI.GBA plasmid produced supraphysiological levels of human GCase of the correct size protein (≈60kDa) when compared to the physiological levels in untransfected cells ( Fig. 2B ). Subsequent quantification of the relative protein expression revealed that transfected cells expressed 6-fold higher GCase than untransfected controls ( Fig. 2C ). An enzymatic activity assay was then performed to confirm that the human GCase was functional. This showed that the enzymatic activity of GCase extracted from transfected cells was 5-fold higher than the endogenous levels in untransfected cells (Fig. 2D) . The supernatant was also tested in order to demonstrate that functional GCase was secreted from cells.
GCase enzymatic activity in the supernatant was higher in the transfected samples than in the controls.
To evaluate potential toxicity from administration of a high dose of the AAV9.hSYNI.hGBA vector, CD1 wild-type mice were intravenously injected with 2.4x10 12 vg of the viral vector at the day of birth. The animals were sacrificed after one month and the brains were assessed for the presence of a neuroinflammatory response. Sections of brain from injected mice (WT + AAV) and uninjected animals (WT -AAV) were examined by immunohistochemistry using an antibody against the astrocytic marker GFAP ( Fig. 2E ). We did not observe any hypertrophy or activation of astrocytes in any region of the brains from administered mice. The level of immunoreactivity in the barrel field of the somato-sensory cortex (S1BF), cornu annuli 1 and 2 of the hippocampus (CA1/CA2) and the ventral posteromedial and posterolateral nuclei of the thalamus (VPM/VPL) was measured ( Fig. 2F ). Quantification of GFAP staining confirmed that the staining intensity was comparable to the uninjected agematched littermate controls, with no statistical difference between injected and uninjected mice.
Extension of lifespan and assessment of neurological manifestation in K-
14-lnl/lnl mice treated with AAV9.hSYNI.hGBA.
Having shown that neonatal gene delivery was effective and overexpression of GCase did not promote neurotoxicity in the brain of injected animals, 2.4x10 12 vg of the AAV9.hSYNI.hGBA vector was administered intravenously to five Gba knock-out mice (K14-lnl/lnl) on the day of birth. Age-matched wild-type mice and untreated knock-out mice were used as controls. Consistent with previous studies, untreated knock-out mice developed progressive neurological symptoms at 10 days after birth and reached their humane end-point at two weeks of age, at which point they displayed advanced tetraparesis and seizures.
The administration of gene therapy resulted in a significant extension of the lifespan of all treated knock-out mice (Fig. 3A) . Treated knock-out and wild-type mice were sacrificed at nine weeks of age. For the duration of the experiment the body weight of the animals was monitored weekly ( Fig. 3B ). Treated K14lnl/lnl mice gained weight throughout their lifespan, although there was a trend towards them being smaller than the age-matched controls, albeit not statistically significant.
Neurological manifestations in treated mice and wild-type controls were assessed by a series of behavioural tests. K14-lnl/lnl mice exhibited motor dysfunction and paralysis at two weeks of age, where they were completely unable to return to prone position when placed in supine position. At P14, untreated knock-out mice failed the self-righting reflex test (score 0), while all treated mice and wild-type controls were significantly better at being able to right themselves in less than 1 second (score 1) ( Fig. 3C ). At this stage, untreated animals were too severely affected and could not undergo any further neurobehavioural assessment. At 60 days of age treated knock-out mice did not show obvious symptoms of loco-motor dysfunction when placed on the rotarod apparatus, although the average time at fall was slightly shorter than the littermate controls, but not statistically significantly so (Fig. 3D ). Cerebellar ataxia was assessed by monitoring limb clasping phenotype (Fig. 3E ). While K14wt/wt controls extended all four limbs when suspended by the tail (score 0), P66 treated mice showed a diverse phenotype. One animal displayed severe clasping on both limbs (score 2), three mice showed a mild hind limb clasping behavior, and one mouse did not show any clasping phenotype comparable to wild-types.
An open field analysis showed that P66 treated K14-lnl/lnl mice performed equally to wild-type littermates in terms of distance travelled, average speed, time in motion and time immobile ( Fig. 3F ). From the movement traces it was possible to observe that treated animals showed exploratory behavior and did cross the centre of the chamber several times, comparable to the wild-type controls. Motor coordination was also assessed by counting the number of paw misplacements over 1 minute when P66 animals were free to walk on a grid ( Fig.   3G ). Both treated knock-out mice and wild-type controls missed a comparable number of paw placements, showing no significant difference. Foot print analysis ( Fig. 3H ) was used to evaluate gait in treated and control mice at 9 weeks of age.
Stride length and base width was measured ( Fig. 3I ), demonstrating that treated K14-lnl/lnl mice did not show ataxic movement, averagely maintaining regularbase gait and constant step length.
Neuropathology analysis of brains from AAV9.hSYNI.hGBA treated K14lnl/lnl mice.
At 66 days of age, treated K14-lnl/lnl mice and age-matched wild-type controls were sacrificed and immunohistological analysis was performed. Brain sections of controls, treated knock-out and untreated mice were stained with an antibody against the GCase protein and the most affected regions observed in Gaucher patients were analysed (Fig. 4A ). Widespread AAV9.hSYNI.hGBA-mediated expression of GCase was detected in neurons throughout the whole brain of injected mice, particularly in the cortex, hippocampus, thalamus, cerebellum and brain stem. Quantification of immunoreactivity confirmed that systemic administration of the vector resulted in increased GCase expression compared to untreated affected mice, especially in the thalamic nuclei VPM/VPL and the cerebellar lobe 10Cb (Fig. 4B ). GCase enzymatic activity was measured in frozen brain homogenates ( Fig. 4C ). Enzymatic activity in the brain of treated knock-out mice was on average 68% of wild-type levels, but statistically there was no significant difference between the two groups, while end-stage untreated mice retained around 10-16% of residual enzymatic activity consistent with what was previously shown in (25) . Glycosphinglipid (GSL) profile analysis was also conducted on brain homogenates ( Fig. 4D ). Most GSL species were not elevated in young P14 knock-out mice and in older P66 treated mice. However, GM1a, GD1a, and GT1b levels were significantly elevated in young untreated P14 knockout brains compared to both older P66 wild-type and P66 treated knock-out mice. GD1b was elevated in untreated Gba knock-outs compared to wild-type controls, but there was no significant difference with treated K14-lnl/lnl mice.
Brain sections underwent additional immunohistochemical staining using the Cluster of Differentiation 68 (CD68) marker ( Fig. 5A ). Intense and diffuse staining was observed in brains of P14 untreated K14-lnl/lnl mice. Higher magnification light microscopy revealed hypertrophic activated microglia morphology. Microglia activation was normalised in brains of P66 treated mice; CD68-positive staining was similar to that in brain sections from age-matched controls. Higher magnification of microglia in brain sections from treated mice also revealed a resting morphology identical to those observed in control wildtype mice. This result was corroborated by quantification of immunoreactivity ( Fig. 5C ). In all analysed brain regions CD68 staining was significantly elevated in untreated knock-out mice compared to both treated mice and wild-type controls.
Quantification revealed no significant difference in CD68 staining between treated and age-matched wild-type controls, indicating sustained prevention of any microglia-mediated inflammatory response.
The GFAP marker was used to assess an astrocyte-mediated inflammatory response ( Fig. 5B ). Examination of brain sections from P14 untreated K14-lnl/lnl mice showed extensive and diffuse astrogliosis in all areas examined and higher magnification revealed hypertrophy of labelled cells. The sections from treated K14-lnl/lnl mice exhibited a normalisation of the GFAP immunopositivity and were comparable to sections from wild-type mice, with the exception of the brain stem. In this region there was a reduction in the inflammatory response but it did not appear to be comparable with wild-type levels. These observations were partially supported by quantification of staining showing that the administration of the AAV9.hSYNI.hGBA vector resulted in significant reduction of neuroinflammation in treated mice in the S1BF cortical region and the VPM/VPL thalamic nuclei compared to untreated knock-out animals and no significant difference from wild-type animals ( Fig. 5D ). However, in the CA1/CA2 regions of the hippocampus and the Gi region of the brain stem, the levels of GFAP staining were still significantly higher than those measured in control wildtype mice.
Sections were also stained for the Lysosome-Associated Membrane Protein 1 (LAMP1) ( Fig. 6A ). Lysosomal accumulation is observable in the brain of K14lnl/lnl mice in all regions examined. This was not the case in the brains from treated mice that were comparable to those from wild type controls.
Quantification of the immunoreactivity (Fig. 6B ) confirmed the significant increase in LAMP1 staining in all brain regions in brain sections from K14lnl/lnl, while the lysosomal marker levels were completely normalised to wildtype level in all analysed brain regions of treated mice.
Gene therapy prevents neuronal loss in treated K14-lnl/lnl brains.
We have previously demonstrated that the P12 Gba knock-out mice present reduced cortical thickness and significant neuron loss in different brain regions (20) . Therefore brain sections from P66 treated mice and wild-type controls were stained with Nissl coloration and a stereological analysis was performed in order to assess brain atrophy and neuronal counts in age-matched animals.
Macroscopic examination of the anatomical architecture by light microscopy did not highlight any obvious abnormalities ( Fig. 7A ). Measurements of cortical thickness in the S1BF region demonstrated no differences between treated K14lnl/lnl mice and age-matched wild type controls (Fig. 7B ).
In order to establish whether the treatment with AAV9.hSYNI.hGBA ameliorated the neurodegeneration in treated mice, neuronal counts were performed using the stereological technique combining optical dissector and fractionator. The number of neurons was evaluated in the S1BF cortical region, the VPM/VPL thalamic nuclei and the Gi region in the brain stem ( Fig. 7C ). Neuron counts in brains harvested from P66 treated knock-out mice were comparable to agematched wild-type controls in all analysed regions, demonstrating that gene therapy prevents neuronal loss in treated animals.
A non-quantitative analysis of Purkinje neurons in the cerebellum was conducted. Cerebellar sections were stained using the Purkinje neuron-specific marker calbindin and light microscopy images were taken (Fig. 7D ). The examination of high magnification images revealed that there was no evident Purkinje cell loss in cerebella from P66 treated knock-out mice, while fewer neurons were detected in the tissue of P14 end-stage untreated K14-lnl/lnl animals.
Effects of gene therapy on the visceral pathology.
We have previously shown that an intravenous administration of an AAV9 vector expressing GBA under the control of the ubiquitous GUSB promoter can ameliorate visceral pathology in the K14-lnl/lnl mouse model. Since evidence of hSynI-mediated gene expression within visceral organs and cells of non-neuronal lineage have been shown, amelioration of the visceral pathology following intravenous gene therapy was evaluated. Organomegaly is one of the most common systemic manifestations in patients and is recapitulated in the longterm intracerebroventricular treated mouse model (20) . Gene therapy prevented enlargement of the spleen in 9-week old treated mice with no significant difference compared to measurements from wild type mice ( Fig. 8A) .
Sections from the liver, spleen, lung and heart were stained with hematoxylin and eosin dye ( GCase enzymatic activity remained significantly lower in liver, lung and heart samples from treated mice, in which GCase activity was less than 10% of wildtype levels (Fig. 8E ). Spleen from treated animals had 43% of enzymatic activity compared to wild-type controls. Untreated K14-lnl/lnl mice had residual enzyme activity ranging between 1% and 7% of wild-type levels in all visceral organs.
Although the enzymatic activity in tissues harvested from treated mice was not normalised to wild-type levels, GCase activity was greater in P66 treated animals than younger Gba knock-out untreated mice.
Discussion
Viral gene therapy offers the unique opportunity to obtain long-lived therapeutic effects, particularly for neurological diseases where the treatment needs to reach restricted tissues such as the brain and achieve high levels of transduction (27) .
Because of its ability to cross the blood-brain barrier following systemic administration (21) AAV9 is widely used for gene delivery to the central nervous system in several preclinical studies (28) as well as in recent clinical trials for other LSDs (NCT02716246, NCT03315182) and Spinal Muscular Atrophy (NCT03505099) (29) .
We have previously demonstrated that an acute mouse model of nGD can be rescued long-term from neurodegeneration-associated death by a single intravenous administration of an AAV vector at birth (20) . While encouraging, the neuropathology was not completely prevented. Here we designed a gene therapy vector with a strong neuron specific synapsin I promoter to improve gene expression in the central nervous system following systemic administration to a mouse model of nGD.
Firstly, we conducted a systemic gene expression study using the eGFP reporter driven by the synapsin promoter. Neonatal intravenous administrations of the viral vector resulted in widespread and intense neuron-specific expression in the brain of injected mice. Surprisingly, systemic gene delivery of the neurotrophic vector resulted in eGFP expression in non-neuronal cells in visceral organs, such as the liver and spleen. Having confirmed the potential use of the vector and established that overexpression of GCase in the brain did not cause neurotoxicity, we proceed in administering gene therapy to neonatal Gbadefective mice. The treatment resulted in significant extension of life span, prevented weight loss and ameliorated indices of locomotor and behavioural deficits.
The K14-lnl/lnl model is one of the most aggressive mouse models of neurovisceral metabolic diseases, the treatment of which requires an early intervention to rescue it from death at 12-14 days of age. The ability of the vector to rescue the nGD mice given the short window of therapeutic intervention, even when administered at birth, is encouraging particularly if taking into consideration that the viral vector used carried a single-stranded DNA genome.
The conversion into double-stranded DNA is necessary to commence gene expression and is considered to be a limiting factor that influences expression time and rate mediated by ssAAV vectors (30) . In spite of the presence of neuropathology already on the day of birth (20) AAV9.hSYNI.hGBA prevented neuronal loss in treated Gba knock-out mice with neuron counts comparable to those of wild-type controls in key areas of the brain. This represents a significant improvement in what we have previously reported, where neonatal intravenous administration using a self-complementary vector with GBA gene under control of the ubiquitous beta-glucuronidase promoter (AAV9.GUSB.hGBA) did not provide complete neuroprotection. The AAV9.hSYNI.hGBA vector also carries the WPRE enhancing element downstream of the hGBA transgene, which is known to increase transgene expression of single-stranded AAV vectors when administered intravenously (22) .
We previously demonstrated that intravenous administration of 4x10 11 vg of AAV9.GUSB.hGBA to neonatal Gba knock-out mice resulted in significant increase in their lifespan but only partially ameliorated the neuropathology in P60 treated animals. In fact, despite the widespread overexpression of GCase throughout the brain, some areas were still affected by substantial neuroinflammation and neuropathology. With the aim of increasing neuronal transduction following systemic administration, we increased the dose of the new vector to 2.4x10 12 vg (2.4x10 15 vg/kg). Such high dose has not been used in the clinic yet, and might not be effectively translatable. However the present work is a proof-of-concept study, aiming to demonstrate that a more efficient brain transduction is essential to increase the therapeutic outcome in the heavily affected brains of this acute mouse model.
Here we showed that the use of a neuron-specific vector completely normalised microglia activation in mice treated with AAV9.hSYNI.hGBA. This effect was especially evident in the S1BF cortical region, which was characterised by extensive microglia activation in mice injected with AAV9.GUSB.hGBA. The reduction of CD68-positive cells in AAV9.hSYNI.hGBA treated mice was associated with normalisation of neuron count in cortex, thalamus and cerebellum. These results supported the hypothesis according to which microglia activation temporally correlates with neuronal loss in defined brain regions (31) . As a similar pathological pattern is observed in human patients, our findings might be an additional contribution to the development of a possible clinical intervention. The use of a neuron-targeted vector led to significant increase of GCase activity in the brain, although the enzyme levels were not completely normalised to wild-type levels. Nevertheless, even reduced levels of residual enzymatic activity can be sufficient to achieve significant therapeutic improvements. This hypothesis is sustained by the fact that heterozygote mice show lower GCase activity than wild-type in the brain and yet do not present neuropathology (25, 20) . Severe neuron loss and cerebral atrophy in the somatosensory region is characteristic of nGD. Reduction of cortical thickness was prevented in AAV9.hSYNI.hGBA treated mice. In addition, cortical thinning is often accompanied by ventriculomegaly in different types of lysosomal storage disorders (32) . No indication of pathological enlargement of the ventricles was present in treated mice. Together our results demonstrated that preventing glucosylceramide accumulation in neurons rescued the acute and widespread neurodegeneration characteristic of neuronopathic Gaucher disease.
Administration of neuron-targeted gene therapy also led to normalisation of astrogliosis in the cortex and thalamus, regions which contained considerable numbers of activated astrocytes in AAV9.GUSB.hGBA treated mice. Nevertheless, significant astrogliosis was detected in the hippocampal region CA1/CA2, cerebellum and the gigantocellular nuclei area of the brain stem of animals injected with AAV9.hSYNI.hGBA. Since we achieved complete neuroprotection in the areas examined and the microglial-mediated inflammatory response was prevented, it is possible that cross-correction to astrocytes is insufficient to prevent activation. However, this needs to be taken in the context that the role of astrocytes in nGD is not well understood and that the specific stimuli triggering neuroinflammation in lysosomal storage diseases have not been completely clarified.
Although human synapsin is a neuron-specific promoter, it has been shown that it drives expression in the liver following systemic administration in rodents (33) . Evidences of low levels of vector-mediated gene expression were detected in the viscera of injected mice. Transduced liver cells might function as metabolic factory for the production of β-glucocerebrosidase. However, the effects of circulating enzyme were not sufficient to significantly ameliorate the pathology in all the visceral organs, particularly in the lung where tissue-resident macrophages (34) can still be impaired. Nevertheless, overall accumulation of Gaucher cells was partially reduced in 66-day-old treated mice compared to younger untreated knock-outs. Since visceral pathology is successfully improved by enzyme replacement therapy, the possible combination with neuron-targeted gene therapy might be considered as a beneficial treatment option of nGD patients.
Systemic delivery of AAV9 in two different nGD mouse models has been already attempted by Du and colleagues (35) . Intravenous injection of an AAV9.CMV.Gba vector expressing the murine wild-type gene was administered 30 days before tamoxifen induction to Gba(flox/flox),UBC-CreERT2 mice, resulting in extension of the life span and increased GCase activity in the brain, liver and spleen of treated mice. An AAV9 vector with the synapsin promoter was also used to deliver the mouse Gba gene to P5 Gba(flox/flox), Nestin-Cre mice (25) via intraperitoneal injection. The treatment resulted in extended survival, amelioration of the neurodegeneration, but did not normalise enzymatic levels in the liver. Despite the overall positive results, the preventive or delayed AAV treatment might represent a possible therapeutic approach only for those type 3 patients displaying mild and late-onset neurological symptoms. However, we suggest that an early intervention is the only viable treatment option for type 2 patients, where the acute and lethal neurodegeneration is already present at birth (13) .
Intravenous administration of AAV9 vectors is minimally invasive and results in broad transduction of the central nervous system. The recent clinical trial of gene therapy for Spinal Muscular Atrophy further supports the efficacy and safety of this approach. However, we appreciate that the large dose of vector needed for a systemic intervention must be considered in terms of scalability and manufacturing costs. The possible immune response to high dose gene therapy must also be evaluated, although the SMA clinical trial showed that increased levels of transaminases in treated patients were successfully managed by prophylactic treatment with prednisolone.
The use of a single vector as unified treatment for the whole Gaucher patient population is an attractive therapeutic option. However, different vectors configurations and novel engineered capsids can be considered in order to enhance transduction efficiency and specificity, and possibly reduce the viral load. The AAV-PHP.B variants (36, 37) for example showed incredible CNS transduction efficiency when administered intravenously to rodents, however as of today the superior characteristics of these new engineered capsids have not translated across different models and species (38) . The use of strong ubiquitous promoters, enhanced synthetic promoters and optimised transgene sequences can improve gene delivery and expression in different organs, with greater therapeutic effects on both the neurological and visceral pathology.
In conclusion, our study validated neuron-targeted gene therapy as a potential option for the treatment of severe neurodegeneration in Gaucher disease, for which there is currently no cure. Nevertheless, we suggest that gene delivery limited to neurons only might not be sufficient in the long term. 
Virus production
HEK-293T cells were transfected as described in (26) 
In vivo animal studies
The K14-Cre colony was maintained as heterozygous. Pups were genotyped at birth through GCase enzymatic assay on dried blood spot samples. Blood samples were taken from the temporal vein and blotted on filter paper 
Animal behavioural analysis
Rotarod test -Mice were trained for three days before performing the tests. The rotarod (Panlab LE8200, Cornella, Spain) was set with a start speed of 4 rpm and 20 rpm/min acceleration. When a mouse fell off the time and speed was noted, up to three times per experiment. If the mouse fell within the first 5 seconds due to poor placing, the experiments would not be recorded. Hind limb clasping test -Hind limb clasping phenotype was evaluated following the protocol described in (39) . The mouse was suspended by the end of its tail approximately 20cm from the bench, ensuring that the animal cannot grasp its tail. The test was recorded for 1 minute with a camera facing towards the abdomen of the mouse. The clasping phenotype was scored as following: all limbs extended out from the body all the time = 0; hind limbs extended out most of the time; one hind limb retracted in a clasping position less than 50% of the time = 1; both hind limbs partially retracted for more than 50% of the time = 2; hind limbs exhibit a clear clasping phenotype touching the abdomen for more than 50% of the time = 3.
Open field test -
Righting reflex test -The mouse was placed in a supine position on a flat surface and rapidly released. The ability of the mouse to right itself (four paws on the ground) was assessed. Fast latency to return to prone position (< 1 second) was scored 1, while animals with impairments in motor coordination functions and slow latency to right their selves (>10 seconds) were scored 0.
Foot fault test -The mouse was placed on a metal mesh surface (mesh gap size 1.3cm) elevated 20cm from the bench. The animal was allowed to cross the device from a 'start cage' to the 'home cage'. The run was recorded over one minute. The number of total steps for fore limbs and hind limbs was manually counted. The number of foot faults, defined as misplacement of a paw slipping through the grid, was also manually counted.
Footprint pattern test -The paws of the mouse were painted with different coloured non-toxic dyes (fore paws: blue; hind paws: red). The animal was then allowed to walk along a corridor 10cm wide, leaving a trail of footprints on a paper sheet 60cm long. The mouse was trained to spontaneously walk through the corridor for three times before recording the experiment. The stride length and base width were manually measured.
Histological analysis
Fixed organs were frozen and cut at 40μm in thickness at constant temperature of -20°C with a Cryostat Leica CM3050 (Leica Biosystems, Milton Keynes, UK).
A series of representative sections was collected and washed with 1X trisbuffered saline (TBS). Endogenous peroxidase activity was blocked with 1% H2O2 in 1X TBS for 30-60 minutes under constant gentle agitation. Slices were rinsed in TBS and the non-specific binding was blocked in 15% normal serum (Sigma-Aldrich) in TBS-T (0.3% Triton X-100 in 1X TBS) for 30 minutes in agitation. Sections were incubated at 4°C overnight with the primary antibody for eGFP (1:1,000, ab290, Abcam), GCase (1:1,000, G4171, Sigma-Aldrich), CD68
(1:2,000, MCA1957, AbD Serotech, Kidlington, UK), GFAP (1:1,000, MAB3402, Millipore), LAMP1 (1:2,000, ab24170, Abcam), calbindin (1:10,000, CB38, Swat, Marly, Switzerland) diluted with 10% normal serum in TBS-T. The following day, slices were washed with 1X TBS and incubated for 2 hours at room temperature with the secondary biotinilated antibody anti-mouse, anti-rabbit or anti-rat IgG Light bright-field images were taken with a Nikon DS-Fi1 camera (Nikon, Tokyo, Japan) attached to a Nikon Eclipse E600 microscope. Representative images of discrete areas of the sections were taken with 10X/0.25 and 40X/0.65 objectives (CFI Achromat, Nikon).
Immunofluorescent stained sections were analysed with Zeiss LSM 710 laser scanning confocal microscope (Carl Zeiss AG, Oberkochen, Germany).
Staining quantification
The quantification of immunohistochemical staining was conducted as described in (20) . Briefly Neurons were counted with the optical fractionator probe using the 40X objective. The grid size and the counting frame used for analysing different brain regions were the following: S1BF 150 x 150 μm, 50 x 50 μm; VPM/VPL 175 x 175 μm, 50 x 50 μm; Gi 100 x 100 μm, 50 x 50 μm. Cells were counted using a 100X objective. Efficient sampling was estimated by a coefficient of error between 0.05 and 0.1 (40) .
The mean thickness of the S1BF cortical region was estimated by using the Cavalieri vertical sections principle (41) . The length of 10 parallel consecutive lines intersecting perpendicularly the cerebral cortex, traced from the somatosensory barrel cortical layer 1 to the corpus callosum, was measured.
Enzymatic assay
Frozen samples were first homogenised in distilled water and consequentially 
Glycosphingolipid profile analysis
Glycosphingolipids (GSLs) from brain homogenates were analysed as described in (20) . Briefly, GSLs were extracted in chloroform:methanol (1:2 v/v) overnight at 4°C and then purified using solid phase hydrophobic C18 chromatography columns (Kinesis, Neots, UK). The GSLs were then digested overnight to release glycan headgroups with recombinant Endoglycoceramidase I (gifted from Orphazyme), or with Cerezyme (Sanofi Genzyme) to release glucose from glucosyl-ceramide. Liberated glycans and glucose were then labeled with anthranillic acid (2-AA). The resulting 2AA-labeled glycans were purified and separated from the fluorescent label using Supelco DPA-6S solid phase extraction columns (Sigma-Aldrich) and then applied to normal-phase highperformance liquid chromatography (NP-HPLC). Integrated peaks from the chromatogram were quantified using a 2AA-labelled chitotriose standard and normalised to total protein content.
Statistics
The statistical analysis was performed with GraphPad Prism Software (v. 6.0e). Immunochemical staining of brain sections for the astrocyte marker GFAP and (D) quantification of immune reactivity in cortex (S1BF), hippocampus (CA1/CA2), thalamus (VPM/VPL), cerebellum (10Cb) and brain stem (Gi). Gene therapy partially reduced neuroinflammation in cortex, thalamus and brain stem of K14-lnl/lnl treated brains. Scale bars: low magnification 100 μm; high magnification 60 μm. 
